Drugs / Inactivated Influenza Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02289820 | Jan 2015 → Feb 2016 | respiratory syncytial virus infectious disease | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated Influenza Vaccine | “Inactivated Influenza Vaccine (IIV)” NCT02289820 ↗ |
| Known as | IIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02289820 ↗ |
| Modality | Vaccine | “This is the second phase 1 study of a respiratory syncytial virus (RSV) vaccine containing RSV fusion protein (sF) adjuvanted with glucopyranosyl lipid A (GLA) in a...” PMID 28679495 ↗ Sep 2017 |
| Route | Intramuscular | “Participants will receive a single dose of IIV by intramuscular injection” NCT02289820 ↗ |